Journal of Diabetes & Metabolic Disorders

, Volume 17, Issue 2, pp 393–399 | Cite as

The basal to total insulin ratio in outpatients with diabetes on basal-bolus regimen

  • Elena CastellanoEmail author
  • R. Attanasio
  • V. A. Giagulli
  • A. Boriano
  • M. Terzolo
  • E. Papini
  • E. Guastamacchia
  • S. Monti
  • A. Aglialoro
  • D. Agrimi
  • E. Ansaldi
  • A. C. Babini
  • A. Blatto
  • D. Brancato
  • C. Casile
  • S. Cassibba
  • C. Crescenti
  • M. L. De Feo
  • A. Del Prete
  • O. Disoteo
  • F. Ermetici
  • V. Fiore
  • A. Fusco
  • D. Gioia
  • A. Grassi
  • D. Gullo
  • F. Lo Pomo
  • A. Miceli
  • M. Nizzoli
  • M. Pellegrino
  • B. Pirali
  • C. Santini
  • S. Settembrini
  • E. Tortato
  • V. Triggiani
  • A. Vacirca
  • G. Borretta
  • all on behalf of Associazione Medici Endocrinologi (AME)
Open Access
Research Article



To evaluate the basal/total ratio of daily insulin dose (b/T) in outpatients with diabetes type 1 (DM1) and type 2 (DM2) on basal-bolus regimen, by investigating whether there is a relationship with HbA1c and episodes of hypoglycemia.


Multicentric, observational, cross-sectional study in Italy. Adult DM1 (n = 476) and DM2 (n = 541) outpatients, with eGFR >30 mL/min/1.73 m2, on a basal-bolus regimen for at least six months, were recruited from 31 Italian Diabetes services between March and September 2016. Clinicaltrials.govID: NCT03489031.


Total daily insulin dose was significantly higher in DM2 patients (52.3 ± 22.5 vs. 46 ± 20.9 U/day), but this difference disappeared when insulin doses were normalized for body weight. The b/T ratio was lower than 0.50 in both groups: 0.46 ± 0.14 in DM1 and 0.43 ± 0.15 in DM2 patients (p = 0.0011). The b/T was significantly higher in the patients taking metformin in both groups, and significantly different according to the type of basal insulin (Degludec, 0.48 in DM1 and 0.44 in DM2; Glargine, 0.44 in DM1 and 0.43 in DM2; Detemir, 0.45 in DM1 and 0.39 in DM2). The b/T ratio was not correlated in either group to HbA1c or incidence of hypoglycemia (<40 mg/dL, or requiring caregiver intervention, in the last three months). In the multivariate analysis, metformin use and age were independent predictors of the b/T ratio in both DM1 and DM2 patients, while the type of basal insulin was an independent predictor only in DM1.


The b/T ratio was independent of glycemic control and incidence of hypoglycemia.


Insulin therapy Hypoglycemia Basal bolus Type 1 diabetes Type 2 diabetes 



basal to total daily insulin dose ratio


confidence intervals


glycated hemoglobin


estimated glomerular filtration rate


high pressure liquid chromatography


other antidiabetic drugs


standard deviation


type 1 diabetes


type 2 diabetes


Insulin is the most effective drug for the treatment of diabetes [1]. Basal-bolus regimen is the most recommended approach for insulin-treated patients with diabetes, as it reflects the physiological insulin secretion and improves glycemic control more safely than other insulin regimens [2, 3]. The basal-bolus insulin regimen is the starting treatment for individuals with type 1 (DM1) diabetes, whereas in patients with diabetes type 2 (DM2), it is the final step when an optimal glycemic control is not obtained with other antidiabetic drugs (OADs), or these are contraindicated.

Current guidelines [1, 3] provide few recommendations regarding the distribution of insulin doses for the basal-bolus regimen. In a hospital setting, 60–80% of the total (i.e. basal plus bolus units) daily insulin dose is recommended in DM1 and DM2 patients transitioning to outpatient subcutaneous insulin [1]. The American Association of Clinical Endocrinologists (AACE) guidelines also recommend starting subcutaneous insulin treatment in DM2 patients by halving the total daily dose between basal and prandial fractions, the latter divided into three doses before meals [3]. In fact, the subdivision of total daily insulin dose in real life is not evidence based and its association with glycemic control is still unresolved.

Our multicentric, observational, cross-sectional study aimed to evaluate the basal/total ratio of daily insulin dose (b/T) in a large series of DM1 and DM2 patients by looking for a possible relationship with the glycemic control (as evaluated by HbA1c) and the occurrence of hypoglycemia.

Patients and methods

Design and protocol

From March 2016 to September 2016, we performed an observational, cross-sectional, multicenter study in outpatients with DM1 and DM2 diabetes. The study was commissioned by the Italian Association of Clinical Endocrinologists (Associazione Medici Endocrinologi - AME) and approved by the Ethical Committee of Cuneo Hospital (BASAL Study— OSS 001/2016 – rif ENDO 30). The ID is NCT03489031. The research was open to all specialists taking care of patients with diabetes in Italy.

The primary endpoint was glycemic control, evaluated by HbA1c levels, according to b/T.

Secondary endpoints were occurrence of major hypoglycemic episodes according to b/T; differences between patients with DM1 and DM2.

An ad hoc form was developed and used to record all medical findings. The form was emailed to all participating centers that then emailed or faxed it back to our data manager. Data were checked for accuracy.

The following data were required: age, gender, body weight and height, country of origin, type of diabetes and its duration, units of basal and total (basal plus prandial) daily insulin, type of basal insulin (Glargine, Detemir or Degludec), use and dosage of metformin, and number of major hypoglycemic episodes (<40 mg/dL or requiring caregivers intervention) in the last three months. Serum creatinine and HbA1c levels obtained within the previous two months were also required.


Each participating center recruited between 20 and 40 outpatients with diabetes. Inclusion criteria were as follows: adult outpatients (≥20 and ≤ 80 years) with DM1 or DM2, on basal-bolus insulin regimen (basal bedtime insulin, i.e. Glargine, Detemir or Degludec, plus at least two prandial insulin shots with insulin short acting analogs) for at least six months, usually assuming three daily meals, and capable of informed consent.

Exclusion criteria: pregnancy or breast-feeding, severe liver or renal failure (eGFR <30 mL/min/1.73 m2), use of OADs (only metformin was allowed); hospitalization for any cause, glucocorticoid or oncologic treatment, or patients who had performed Ramadan in the last six months.

Patients gave their informed consent, and the Institutional Review Board of each participating center approved the study. All procedures followed were in accordance with the ethical standards of the Helsinki Declaration of 1964, as revised in 2013.


All biochemical parameters were analyzed in the laboratories of each participating center. HbA1c was assayed by the ion-exchange HPLC method. Serum creatinine levels were assayed by automated analysis using a colorimetric method. eGFR was calculated using the CKD-EPI formula [4], namely:
$$ \mathrm{eGFR}={141}^{\ast }\ \min\ \left(\mathrm{SCr}/\mathrm{k},1\right)\ {\upalpha}^{\ast }\ \max\ \left(\mathrm{SCr}/\mathrm{k},1\right)-{1.209}^{\ast }\ 0.99{3}^{\ast}\mathrm{Age}\ \left[\ast 1.018\ \mathrm{if}\ \mathrm{women}\ \right]\ \left[\ast 1.159\ \mathrm{if}\ \mathrm{black}\right], $$
where SCr represents serum creatinine (in mg/dL), k represents 0.7 for women and 0.9 for men, α represents −0.329 for women and − 0.411 for men, min represents the minimum of SCr/k or 1, and max represents the maximum of SCr/k or 1.

Patient body mass index (BMI) was calculated as the body weight in kilograms divided by the square of the body height in meters.

Statistical analysis

Variables were preliminarily tested for normal distribution with the Shapiro-Wilks W test. Data were expressed as mean ± SD, or median and interquartile range (IQR) as appropriate. Continuous variables with non-normal and normal distribution were analyzed by ANOVA for repeated measures followed by the Tukey test, completely randomized ANOVA followed by the Games-Howell test, Mann-Whitney U test and t test for unpaired samples, respectively, as appropriate. Differences in categorical variables were analyzed by χ2 or Fisher’s test, as appropriate.

Setting b/T as the dependent variable, two separate sets of linear regressions were performed. The first set was univariate; the second included all the variables whose β-coefficient was significant in the univariate analysis. In the case of multiple independent variables, a multicollinearity test was performed. Variables were rejected from the analysis if there was a variance inflation factor greater than 2.

The level of statistical significance was set at p ≤ 0.05 with the Bonferroni correction.

Calculations were performed using SPSS (IBM SPSS Statistics – version 21).


The study was performed in 31 Italian centers, equally distributed among northern, central and southern Italy. We enrolled 1017 patients (aged 56.9 ± 17.7 years), male 57% and female 43%, nearly evenly subdivided between DM1 and DM2, namely 47 and 53%, respectively. Table 1 summarizes the demographic, clinical and biochemical data of the whole study group. DM1 patients were significantly younger, slimmer and with a longer disease duration than DM2 patients. In addition, DM1 patients had a significantly higher eGFR and better glycemic control, but a higher incidence of hypoglycemia.
Table 1

Demographic and clinical data


All (n = 1017)

DM1 (n = 476)

DM2 (n = 541)


Males/Females (%)





Age (years)

56.9 ± 17.7

43.8 ± 15.2

67.9 ± 9.8


Country of origin (Italy/other) (%)





BMI (kg/m2)

28.2 ± 6.7

25.3 ± 4.3

30.8 ± 7.4


Disease duration (years)

18.2 ± 11

19.2 ± 12.5

17.3 ± 9.4


Basal insulin (U/day)

21.5 ± 10.4

20.9 ± 10.2

22.1 ± 10.6


Total insulin (U/day)

49.3 ± 22.0

46 ± 20.9

52.3 ± 22.5


Total insulin daily dose (U/kg)

0.63 ± 0.26

0.63 ± 0.26

0.63 ± 0.26


b/T ratio

0.45 ± 0.15

0.46 ± 0.14

0.43 ± 0.15


HbA1c (%)

7.96 ± 1.4

7.78 ± 1.2

8.1 ± 1.4


HbA1c (mmol/mol)

63.6 ± 14.9

61.5 ± 13.6

65.4 ± 15.6


Metformin users (%)





Mean metformin daily dose (mg)

1723 ± 695

1411 ± 653

1823 ± 671


Creatinine (mg/dL)

0.93 ± 0.3

0.96 ± 0.31

0.90 ± 0.25


eGFR (mL/min/1.73 m2)

89 ± 35

94 ± 36

85 ± 34


Patients with major hypoglycemic episodes (%)





Patients with > 3 hypoglycemic episodes (%)





Type of basal insulin (%)

 • Glargine





 • Detemir








Demographic and clinical data of the whole series. P value is comparing DM1 and DM2 patients

Abbreviations: BMI body mass index; b/t, basal to total insulin ratio; eGFR estimated glomerular filtration rate

Bold points to statistically significant difference

Metformin was used in a greater proportion of DM2 patients than in DM1 patients (40% vs. 13.9%), at higher dosages (Table 1). The relative proportion of patients using the different types of basal insulin, namely Degludec, Detemir and Glargine, was significantly different between DM1 and DM2 patients (p = 0.00001). Total daily insulin dose was significantly higher in DM2 patients, but this difference disappeared if insulin doses were normalized for body weight.

The total insulin daily dose was significantly higher in patients with eGFR >60 mL/min/1.73 m2 than in those with impaired renal function, both in DM1 (54.63 ± 21.61 U vs. 44.33 ± 21 U; p = 0.0001) and in DM2 patients (47.05 ± 20.34 U vs. 34.86 ± 13.27 U; p = 0.00001).

The b/T ratio was lower than 0.50 in both groups, and significantly different between DM1 and DM2 patients (0.46 ± 0.14 vs. 0.43 ± 0.15, respectively, p = 0.011). The b/T was significantly higher in patients taking metformin, in both groups: DM1, 0.52 ± 0.11 vs. 0.45 ± 0.11 (p = 0.00001) and DM2, 0.45 ± 0.11 vs. 0.41 ± 0.11 (p = 0.00001).

In the univariate analysis, the b/T ratio was not related to HbA1c or to the incidence of hypoglycemia, in both DM1 and DM2 patients. In both groups, the b/T ratio was significantly directly correlated to metformin use and inversely correlated to age (Tables 2 and 3). The b/T ratio was significantly influenced by the type of basal insulin, both in DM1 (p = 0.003) and in DM2 (p = 0.021) patients. It was higher with Degludec (0.48 in DM1 and 0.44 in DM2), intermediate with Glargine (0.44 in DM1 and 0.43 in DM2), and lower with Detemir (0.45 in DM1 and 0.39 in DM2).
Table 2

Correlations of b/T in DM1 patients (n = 476) at univariate analysis













Country of origin



Diabetes duration



Type of basal insulin









Hypoglycemia occurrence



Metformin use



Correlations of b/T with demographical and clinical parameters in T1 patients at univariate analysis. R coefficient value is provided for non-categorical variables with p < 0.05

Abbreviations: BMI body mass index; eGFR estimated glomerular filtration rate

Bold points to statistically significant difference

Table 3

Correlations of b/T in DM2 patients (n = 541) at univariate analysis













Country of origin



Diabetes duration



Type of basal insulin









Hypoglycemia occurrence



Metformin use



Correlations of b/T with demographical and clinical parameters in T2 patients at univariate analysis. R coefficient value is provided for non-categorical variables with p < 0.05

Abbreviations: BMI body mass index; b/T basal to total insulin ratio; eGFR estimated glomerular filtration rate

Bold points to statistically significant difference

In the multivariate regression, age, type of insulin and use of metformin were significantly associated with b/T in DM1 (ß = −0.122, p = 0.007; ß = 0.135, p = 0.003; ß = 0.232, p < 0.0001; respectively); only age and use of metformin maintained a statistical relationship with b/T in DM2 patients (ß = −0.099, p = 0.026; ß = 0.134, p = 0.003; respectively).


This large multicentric observational study highlights that in outpatients with diabetes on basal-bolus insulin regimen, the amount of basal insulin is usually less than 50% of the total daily dose. The b/T ratio was significantly different between DM1 and DM2 patients, i.e. 46 and 43%, respectively. Moreover, neither the glycemic control nor the occurrence of hypoglycemia seemed to be linked to the b/T ratio. Conversely, the b/T ratio appeared to be significantly correlated to age and metformin co-administration.

The basal-bolus regimen is widely recommended by the current guidelines for the treatment of patients with DM1 and DM2. In fact this regimen improves glycemic control and reduces hospital complications compared to other conventional therapeutic approaches [2]. Basal-bolus insulin therapy provides a physiological approach to the treatment of patients with diabetes inasmuch as it covers both basal (i.e., overnight fasting and between-meals) and prandial (i.e., glucose excursions above basal levels at mealtimes) insulin needs [5].

Despite the biologically sound foundations of the basal-bolus schedule, the literature data are scant regarding its practical application in real life. For the transition from IV to SC insulin administration in inpatients with diabetes, current guidelines suggest administering 60–80% of the total daily insulin infused dose as basal insulin [1]. The AACE guidelines also recommend that SC insulin treatment in DM2 patients be started by halving the total daily dose between basal and prandial fractions, the latter divided into three doses before meals. The subsequent titration is based on mealtime and fasting glycemic targets [3]. However, evidence is still lacking regarding the practical implementation of basal-bolus insulin regimen in long-term diabetes.

To the best of our knowledge, this is the first study evaluating the b/T ratio in a large series of patients with DM1 and DM2 referred to departments specialized in the care of patients with diabetes. Our findings show that, in real life in Italy, basal insulin is usually less than 50% of the total daily dose. It is unknown whether in other populations the starting insulin dose suggested by guidelines is applied and maintained in the long-term. However, it is likely that the characteristics of the Mediterranean diet [6], usually followed by the Italian population, play a major role in our findings.

The b/T ratio was significantly higher in DM1 than DM2 patients. A variety of factors could account for this finding. Firstly, DM1 patients produce no insulin [7], and higher basal insulin doses are thus necessary in order to cover the insulin needs of overnight fasting. In addition, DM2 patients are on average fatter and with worse glycemic control than DM1 patients. This is thus likely to lead to a higher requirement of prandial insulin in DM2 patients. It is well established that obesity and a sedentary lifestyle, typical of DM2 patients, result in a loss of insulin sensitivity [8], with greater insulin needs at mealtimes. In addition, physical activity has been shown to improve insulin sensitivity and is associated with moderately lower postprandial glucose levels [9, 10].

Finally, the role played by the type of long-acting insulin used cannot be excluded. The b/T ratio was significantly related to the type of basal insulin used. In fact, basal insulin analogs have different pharmacodynamic and pharmacokinetic characteristics, with a clinical impact on timing, flexibility and dose [11]. Analogs with longer duration of action have a prolonged and more consistent glucose-lowering effect [11], thus implying the reduced need for prandial insulin. This mechanism might explain the higher b/T ratio found in patients treated with Degludec.

The b/T ratio was unrelated to the incidence of hypoglycemia in both diabetic groups. Note that only patients treated with long-acting basal analogs were included in our study. International diabetes guidelines [1, 3] all recommend using long-acting basal analogs instead of NPH, to reduce the risk of symptomatic and nocturnal hypoglycemia [12, 13, 14], in terms of a comparable glycemic control [15, 16]. The most recently marketed Degludec, which is a long-acting insulin analog with a prolonged half-life and ultra-flat kinetics [11], is the best choice in DM1 patients requiring lower HbA1c targets with the consequent potential higher risk of hypoglycemia [11, 17].

Hypoglycemia was significantly more frequent in DM1 than in DM2 patients. This could be due to the stricter control of the glycemic target achieved by DM1 patients. In fact, diabetic microvascular complications are reduced in patients achieving a target of HbA1c <7% (53 mmol/mol) [18]. However, further lowering of the HbA1c goal is associated with a substantially increased risk of hypoglycemia, thus outweighing the potential benefits in terms of microvascular complications [19].

We found a direct correlation between the b/T ratio and the use of metformin both in DM1 and DM2 patients. Metformin acts primarily by decreasing the endogenous glucose production, in particular the hepatic gluconeogenesis after a meal [20, 21]. It is conceivable that its use would enable the prandial insulin dose to be reduced.

The daily percentage of basal insulin decreases in patients suffering from renal impairment. It is well known that the kidney plays a pivotal role in insulin metabolism and excretion. Insulin is filtered at the glomerulus and almost completely reabsorbed and degraded by cells lining the proximal convoluted tubules. This mechanism accounts for 50–60% of the renal uptake of insulin, while the remaining 40–50% is removed from the post-glomerular peritubular capillaries [22]. In patients with renal impairment, the insulin half-life is markedly prolonged, particularly for basal insulin [23]. These observations account for the drop in insulin requirements of diabetic patients with reduced eGFR, as well as the significantly lower daily insulin doses in the patients of this series with renal impairment.

We found an inverse correlation between age and the b/T ratio. It is known that ageing promotes insulin resistance in DM1 [24] and in DM2 patients [25], due to the overexpression of fat mass. The fat mass, above all its visceral component, co-regulates fasting plasma glucose [26] and insulin sensitivity [27] in DM1 and DM2 patients of both sexes [28, 29]. All these factors could account for the higher need for prandial insulin in the elderly.

The strengths of this study are inherent in its design, reflecting the current therapeutic approach to diabetes mellitus in real life practice.

As for the limitations, this study focused on a homogeneous population, in terms of ethnicity and lifestyle, from all regions in Italy. These findings cannot therefore be generalized to patients with diabetes from other countries and ethnic groups. We acknowledge that information on carbohydrate consumption, carbohydrate counting education and physical activity are lacking. Moreover, the residual β cell function was not evaluated. This could play a role, in particular in DM2 patients, in influencing insulin requirements and the distribution between prandial and basal insulin. Moreover, it is to take into account that in real world, DM2 obese patients are rarely managed with basal bolus insulin regimen and metformin alone.

Finally, the putative relationship between the b/T ratio and the analyzed outcomes must be interpreted with caution, because the design of the study was cross-sectional and not longitudinal.

In conclusion, in a large series of Italian outpatients with diabetes treated with an insulin basal-bolus regimen, the b/T ratio was lower than 50% and significantly higher in DM1 than in DM2 patients. The b/T ratio was independent of glycemic control and the incidence of hypoglycemia, while it was correlated to metformin use and age in both DM1 and DM2 patients. Further longitudinal studies are necessary in order to define a causal association between the b/T ratio and the efficacy and safety of insulin treatment.



The authors are very grateful to the participating patients for their cooperation. We are indebted to all the physicians of the centers participating in the study.

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.


This trial was not funded.

Compliance with ethical standards


C.E., A.R., B.A., T.M., P.E., G.E., B. A.C., B.A., B.D., C.C., D.F.M.L., D.P.A.,E.F., F.A., G.D., L.P. F., M.A., N.M., P.B., P.M., S.C., T.E., T.V., V.A. and B.G. have nothing to disclose. G.V.A. has participated in advisory panels for Bayer. A.D. has participated in advisory panels for Novartis. C.S. has received research support from Eli-Lilly. D.O. has received research support from Boehringer, Eli-Lilly,Merck Serono, Novartis, Novo Nordisk,Takeda. G.D. is consultant for Boehringer, Sanofi, Takeda. F.V. has received research support from Astra-Zeneca, Eli-Lilly, Novo Nordisk, Bayer, Novartis and Merck Serono. S.S. is on the speakers’ bureau for Boehringer-Ingelheim, Astra-Zeneca, Eli-Lilly,Takeda and Sanofi-Aventis.

Supplementary material

40200_2018_358_MOESM1_ESM.doc (26 kb)
ESM 1 (DOC 26 kb)


  1. 1.
    American Diabetes Association. Standards of medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S1–S27.Google Scholar
  2. 2.
    Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diabetes Care. 2011;34:256–61.CrossRefGoogle Scholar
  3. 3.
    Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2018 executive summary. Endocr Pract. 2018;24(1):91–120.CrossRefGoogle Scholar
  4. 4.
    Kidney disease. Improving global outcomes (KDIGO) CKD work group. 2013 KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.CrossRefGoogle Scholar
  5. 5.
    Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2016;51:417–28.CrossRefGoogle Scholar
  6. 6.
    Tosti V, Bertozzi B, Fontana L. The Mediterranean diet: metabolic and molecular mechanisms. J Gerontol A Biol Sci Med Sci. 2018;73(3):318–26.CrossRefGoogle Scholar
  7. 7.
    Copenhaver M, Hoffman RP. Type 1 diabetes: where are we in 2017? Transl Pediatr. 2017 Oct;6(4):359–64.CrossRefGoogle Scholar
  8. 8.
    Pehmøller C, Brandt N, Birk JB, et al. Exercise alleviates lipid-induced insulin resistance in human skeletal muscle-signaling interaction at the level of TBC1 domain family member 4. Diabetes. 2012;61:2743–52.CrossRefGoogle Scholar
  9. 9.
    Thorp AA, Kingwell BA, Sethi P, Hammond L, Owen N, Dunstan DW. Alternating bouts of sitting and standing attenuate postprandial glucose responses. Med Sci Sports Exerc. 2014;46:2053–61.CrossRefGoogle Scholar
  10. 10.
    Healy GN, Dunstan DW, Salmon J, et al. Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care. 2008;31:661–6.CrossRefGoogle Scholar
  11. 11.
    Goldman J, Kapitza C, Pettus J, Heise T. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. Curr Med Res Opin. 2017 Oct;33(10):1821–31.CrossRefGoogle Scholar
  12. 12.
    Singh SR, Ahmad F, Lal A, Yu C, Bai Z, Bennett H. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180:385–97.CrossRefGoogle Scholar
  13. 13.
    Horvath K, Jeitler K, Berghold A, et al. Long acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613.Google Scholar
  14. 14.
    Monami M, Marchionni N, Mannucci E. Long acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81:184–9.CrossRefGoogle Scholar
  15. 15.
    Owens DR, Traylor L, Mullins P, Landgraf W. Patient-level meta analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100 U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy. Diabetes Res Clin Pract. 2017;124(Suppl. C):57–65.CrossRefGoogle Scholar
  16. 16.
    Bellido V, Suarez L, Rodriguez MG, et al. Comparison of basal-bolus and premixed insulin regimens in hospitalized patients with type 2 diabetes. Diabetes Care. 2015;38:2211–6.CrossRefGoogle Scholar
  17. 17.
    Kalra S, Baruah MP, Niazi AK. Degludec: a novel basal insulin. Recent Pat Endocr Metab Immune Drug Discov. 2012;6(1):18–23.CrossRefGoogle Scholar
  18. 18.
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  19. 19.
    Adler AI, Stratton IM, Neil HAW, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321:412–9.CrossRefGoogle Scholar
  20. 20.
    Inzucchi S, Maggs D, Spollett G, Page S, Rife F, Walton V, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998 Mar 26;338(13):867–72.CrossRefGoogle Scholar
  21. 21.
    Sambol N, Chiang J, O'Conner M, et al. Pharmacokinetics and pharmacodynamics of metformin in healthy subjects and patients with noninsulin-dependent diabetes mellitus. J Clin Pharmacol. 1996 Nov;36(11):1012–21.CrossRefGoogle Scholar
  22. 22.
    Rubenstein AH, Spitz I. Role of the kidney in insulin metabolism and excretion. Diabetes. 1968 Mar;17(3):161–9.CrossRefGoogle Scholar
  23. 23.
    Kulozik F, Hasslacher C. Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin? Ther Adv Endocrinol Metab. 2013 Aug;4(4):113–21.CrossRefGoogle Scholar
  24. 24.
    Orchard TJ, Olson JC, Erbey JR, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10 year follow-up data from the Pittsburgh epidemiology of diabetes complications study. Diabetes Care. 2003;26:1374–9.CrossRefGoogle Scholar
  25. 25.
    DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia, and atherosclerosis. Neth J Med. 1997;50:191–7.CrossRefGoogle Scholar
  26. 26.
    Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Medeau V, Kevorkian JP. Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab. 2008;34(Suppl 2):S43–8.CrossRefGoogle Scholar
  27. 27.
    Lee CC, Glickman SG, Dengel DR, Brown MD, Supiano MA. Abdominal adiposity assessed by dual energy X-ray absorptiometry provides a sex-independent predictor of insulin sensitivity in older adults. J Gerontol A Biol Sci Med Sci. 2005 Jul;60(7):872–7.CrossRefGoogle Scholar
  28. 28.
    Szadkowska A, Madej A, Ziółkowska K, et al. Gender and age-dependent effect of type 1 diabetes on obesity and altered body composition in young adults. Ann Agric Environ Med. 2015;22(1):124–8.CrossRefGoogle Scholar
  29. 29.
    Conway B, Miller RG, Costacou T, et al. Temporal patterns in overweight and obesity in type 1 diabetes. Diabet Med. 2010;27(4):398–404.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2019
corrected publication January 2019

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Elena Castellano
    • 1
    Email author
  • R. Attanasio
    • 2
  • V. A. Giagulli
    • 3
  • A. Boriano
    • 4
  • M. Terzolo
    • 5
  • E. Papini
    • 6
  • E. Guastamacchia
    • 7
  • S. Monti
    • 8
  • A. Aglialoro
    • 9
  • D. Agrimi
    • 10
  • E. Ansaldi
    • 11
  • A. C. Babini
    • 12
  • A. Blatto
    • 13
  • D. Brancato
    • 14
  • C. Casile
    • 15
  • S. Cassibba
    • 16
  • C. Crescenti
    • 17
  • M. L. De Feo
    • 18
  • A. Del Prete
    • 19
  • O. Disoteo
    • 20
  • F. Ermetici
    • 21
  • V. Fiore
    • 22
  • A. Fusco
    • 23
  • D. Gioia
    • 24
  • A. Grassi
    • 25
  • D. Gullo
    • 26
  • F. Lo Pomo
    • 27
  • A. Miceli
    • 15
  • M. Nizzoli
    • 28
  • M. Pellegrino
    • 1
  • B. Pirali
    • 29
  • C. Santini
    • 30
  • S. Settembrini
    • 31
  • E. Tortato
    • 32
  • V. Triggiani
    • 7
  • A. Vacirca
    • 33
  • G. Borretta
    • 1
  • all on behalf of Associazione Medici Endocrinologi (AME)
  1. 1.Department of Endocrinology, Diabetes and MetabolismSanta Croce and Carle HospitalCuneoItaly
  2. 2.Endocrinology ServiceGaleazzi Institute, IRCCSMilanItaly
  3. 3.Outpatient Clinic for Endocrinology and Metabolic DiseasesConversano HospitalConversanoItaly
  4. 4.Medical Physics DepartmentSanta Croce and Carle HospitalCuneoItaly
  5. 5.Internal Medicine, Department of Clinical and Biological SciencesSan Luigi HospitalOrbassanoItaly
  6. 6.Department of Endocrinology and MetabolismRegina Apostolorum HospitalAlbano LazialeItaly
  7. 7.Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare DiseasesBariItaly
  8. 8.Endocrinology, Department of Clinical and Molecular MedicineSant’Andrea HospitalRomeItaly
  9. 9.Metabolism and Diabetes UnitSan Martino HospitalGenoaItaly
  10. 10.District HospitalAzienda Sanitaria LocaleBrindisiItaly
  11. 11.Department of Endocrinology and DiabetesSantissimi Antonio e Biagio HospitalAlessandriaItaly
  12. 12.Medical DivisionRimini HospitalRiminiItaly
  13. 13.Department of EndocrinologyMaria Vittoria HospitalTorinoItaly
  14. 14.Department of Internal Medicine and DiabetologyHospital of PartinicoPartinicoItaly
  15. 15.Internal Medicine DepartmentPapardo HospitalMessinaItaly
  16. 16.Endocrinology and DiabetesPapa Giovanni XXIII HospitalBergamoItaly
  17. 17.Department of Endocrinology and DiabetesSan Giovanni di Dio HospitalFlorenceItaly
  18. 18.Endocrinology UnitCareggi HospitalFlorenceItaly
  19. 19.Outpatient Clinic for DiabetesAzienda Sanitaria LocaleCivita CastellanaItaly
  20. 20.Diabetology DepartmentNiguarda HospitalMilanItaly
  21. 21.Endocrinology and MetabolismIRCCS Policlinico San DonatoSan Donato MilaneseItaly
  22. 22.Angelucci HospitalSubiacoItaly
  23. 23.Antidiabetic Center AIDGaribaldi HospitalNaplesItaly
  24. 24.Department of EndocrinologyVilla Sofia HospitalPalermoItaly
  25. 25.Division of EndocrinologyMauriziano Umberto I HospitalTorinoItaly
  26. 26.Endocrinology, Department of Clinical and Experimental MedicineGaribaldi-Nesima Medical CenterCataniaItaly
  27. 27.Division of EndocrinologySan Carlo HospitalPotenzaItaly
  28. 28.Department of EndocrinologyMorgagni HospitalForlìItaly
  29. 29.Unit of Internal MedicineHumanitas Mater DominiCastellanzaItaly
  30. 30.Department of Endocrinology and DiabetologyBufalini HospitalCesenaItaly
  31. 31.Diabetology ServiceAzienda Sanitaria Locale Na 1NaplesItaly
  32. 32.Diabetology ServiceAugusto Murri HospitalFermoItaly
  33. 33.Department of Internal MedicineImola HospitalImolaItaly

Personalised recommendations